Soluble-HLA-E : A follow up biomarker in Takayasu arteritis, independent of HLA-E genotype
© 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd..
AIM: Disease activity assessment in Takayasu arteritis (TA) is challenging. Human leukocyte antigen E (HLA-E) is shed from endothelium into serum as a soluble molecule (sHLA-E) in response to inflammation. We aimed to study: (i) utility of sHLA-E as a biomarker of disease activity; and (ii) association of HLA-E polymorphism rs1264457 with clinical disease in Asian-Indian TA patients.
MATERIALS AND METHODS: In phase-1, sHLA-E levels were estimated in sera of 50 consecutive TA patients at baseline visit and 27 healthy controls. Serial estimations were performed in 27 of them. In phase-2, DNA of 150 TA patients and 264 healthy controls were genotyped for rs1264457 polymorphism.
RESULTS: At baseline visit, disease was classified as active, stable and grumbling in 23, 18 and nine patients, respectively. sHLA-E levels were higher in active TA (43; interquartile range [IQR]: 25.3-64.6) pg/mL) than stable disease (12.9; IQR: 7.6-21.6 pg/mL) (P = 0.001). At first follow-up visit, sHLA-E levels were numerically higher in active disease than stable disease (P = 0.06) but this trend was blunted at second follow-up. sHLA-E levels increased in 54% versus 25% of patients with persistently active/relapsing and persistent stable course, respectively. rs1264457 polymorphism was not associated with susceptibility to TA and did not affect sHLA-E levels.
CONCLUSION: sHLA-E level is useful as a biomarker of disease activity and course in TA patients. rs1264457 polymorphism is neither associated with susceptibility nor did it influence sHLA-E levels in TA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
International journal of rheumatic diseases - 21(2018), 2 vom: 27. Feb., Seite 532-540 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goel, Ruchika [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers |
|---|
| Anmerkungen: |
Date Completed 27.08.2018 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/1756-185X.13027 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM27111858X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM27111858X | ||
| 003 | DE-627 | ||
| 005 | 20231227125555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/1756-185X.13027 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1223.xml |
| 035 | |a (DE-627)NLM27111858X | ||
| 035 | |a (NLM)28425192 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goel, Ruchika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Soluble-HLA-E |b A follow up biomarker in Takayasu arteritis, independent of HLA-E genotype |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2018 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2017 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd. | ||
| 520 | |a AIM: Disease activity assessment in Takayasu arteritis (TA) is challenging. Human leukocyte antigen E (HLA-E) is shed from endothelium into serum as a soluble molecule (sHLA-E) in response to inflammation. We aimed to study: (i) utility of sHLA-E as a biomarker of disease activity; and (ii) association of HLA-E polymorphism rs1264457 with clinical disease in Asian-Indian TA patients | ||
| 520 | |a MATERIALS AND METHODS: In phase-1, sHLA-E levels were estimated in sera of 50 consecutive TA patients at baseline visit and 27 healthy controls. Serial estimations were performed in 27 of them. In phase-2, DNA of 150 TA patients and 264 healthy controls were genotyped for rs1264457 polymorphism | ||
| 520 | |a RESULTS: At baseline visit, disease was classified as active, stable and grumbling in 23, 18 and nine patients, respectively. sHLA-E levels were higher in active TA (43; interquartile range [IQR]: 25.3-64.6) pg/mL) than stable disease (12.9; IQR: 7.6-21.6 pg/mL) (P = 0.001). At first follow-up visit, sHLA-E levels were numerically higher in active disease than stable disease (P = 0.06) but this trend was blunted at second follow-up. sHLA-E levels increased in 54% versus 25% of patients with persistently active/relapsing and persistent stable course, respectively. rs1264457 polymorphism was not associated with susceptibility to TA and did not affect sHLA-E levels | ||
| 520 | |a CONCLUSION: sHLA-E level is useful as a biomarker of disease activity and course in TA patients. rs1264457 polymorphism is neither associated with susceptibility nor did it influence sHLA-E levels in TA | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a India | |
| 650 | 4 | |a Takayasu arteritis | |
| 650 | 4 | |a large vessel vasculitis | |
| 650 | 4 | |a sHLA-E | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Histocompatibility Antigens Class I |2 NLM | |
| 700 | 1 | |a Kabeerdoss, Jayakanthan |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Hindhumathi |e verfasserin |4 aut | |
| 700 | 1 | |a Danda, Sumita |e verfasserin |4 aut | |
| 700 | 1 | |a Jayaseelan, Visali |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, T Sathish |e verfasserin |4 aut | |
| 700 | 1 | |a Jude, John |e verfasserin |4 aut | |
| 700 | 1 | |a Bacon, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Joseph, George |e verfasserin |4 aut | |
| 700 | 1 | |a Danda, Debashish |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of rheumatic diseases |d 2009 |g 21(2018), 2 vom: 27. Feb., Seite 532-540 |w (DE-627)NLM197180566 |x 1756-185X |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2018 |g number:2 |g day:27 |g month:02 |g pages:532-540 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/1756-185X.13027 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2018 |e 2 |b 27 |c 02 |h 532-540 | ||